Showing 20 of 40 recruiting trials for “Pleural mesothelioma”
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
👨⚕️ Helle Zacho, MD, DMSc, Clinical Professor dept. of Nuclear Medicine, Aalborg University Hospital📍 1 site📅 Started Jan 2025View details ↗
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
Hemithoracic Arc Radiotherapy Post Pleural Decortication
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
👨⚕️ Wang, MD,PhD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences📍 2 sites📅 Started Sep 2024View details ↗
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
SW-682 in Advanced Solid Tumors
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
A Study of Sacituzumab Govitecan in People With Mesothelioma
👨⚕️ Michael Offin, MD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Jun 2024View details ↗
A Study of MT027 in Patients with Pleural Malignant Tumors
Ga-68 FAPI PET Before Immunotherapy
Evaluation of Response by FLT PET in Mesothelioma
Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma
RecruitingNCT06637345 ↗
Identification of Prognostic and Predictive Biomarkers of Toxicity in Patients With Malignant Pleural Mesothelioma and Treated With High Doses of Radiotherapy (MESORTIBO)
👨⚕️ Alberto Revelant, MD, Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS📍 1 site📅 Started Mar 2024View details ↗
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →